BR0013650A - Composições injetáveis de micropartìculas de buprenorfina e seu uso - Google Patents

Composições injetáveis de micropartìculas de buprenorfina e seu uso

Info

Publication number
BR0013650A
BR0013650A BR0013650-6A BR0013650A BR0013650A BR 0013650 A BR0013650 A BR 0013650A BR 0013650 A BR0013650 A BR 0013650A BR 0013650 A BR0013650 A BR 0013650A
Authority
BR
Brazil
Prior art keywords
opioid
partial
agonist
injectable compositions
opioid antagonist
Prior art date
Application number
BR0013650-6A
Other languages
English (en)
Inventor
Thomas R Tice
Jay K Staas
Teresa M Ferrell
Peter Markland
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Publication of BR0013650A publication Critical patent/BR0013650A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "COMPOSIçõES INJETáVEIS DE MICROPARTìCULAS DE BUPRENORFINA E SEU USO". A presente invenção refere-se a uma formulação injetável de agonista parcial de opióide ou antagonista de opióide de liberação lenta a qual compreende um agonista parcial de opióide ou antagonista de opióide em um excipiente de poli(D,L-lactida) com uma pequena quantidade de acetato de etila residual. Na injeção da composição intramuscular, um agonista parcial de opióide ou antagonista de opióide é liberado de maneira controlada por um período de tempo prolongado. A composição encontra uso no tratamento de viciados em heroína e alcoólicos para reduzir consumo das substâncias de abuso. De particular interesse são as drogas bruprenorfina, metadona e naltrexona.
BR0013650-6A 1999-08-27 2000-08-25 Composições injetáveis de micropartìculas de buprenorfina e seu uso BR0013650A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15111299P 1999-08-27 1999-08-27
PCT/US2000/023390 WO2001015699A1 (en) 1999-08-27 2000-08-25 Injectable buprenorphine microparticle compositions and their use

Publications (1)

Publication Number Publication Date
BR0013650A true BR0013650A (pt) 2002-05-07

Family

ID=22537367

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013650-6A BR0013650A (pt) 1999-08-27 2000-08-25 Composições injetáveis de micropartìculas de buprenorfina e seu uso

Country Status (24)

Country Link
US (2) US6495155B1 (pt)
EP (1) EP1212061B1 (pt)
JP (1) JP4913298B2 (pt)
KR (1) KR100730440B1 (pt)
CN (2) CN100387228C (pt)
AT (1) ATE280579T1 (pt)
AU (1) AU765496C (pt)
BR (1) BR0013650A (pt)
CA (1) CA2382577C (pt)
CY (1) CY1106043T1 (pt)
CZ (1) CZ2002728A3 (pt)
DE (1) DE60015370T2 (pt)
EA (1) EA009080B1 (pt)
ES (1) ES2230154T3 (pt)
HK (1) HK1046858B (pt)
HU (1) HUP0203613A3 (pt)
IL (2) IL148343A0 (pt)
MX (1) MXPA02002105A (pt)
NO (2) NO322650B1 (pt)
NZ (1) NZ517997A (pt)
PL (1) PL198334B1 (pt)
PT (1) PT1212061E (pt)
RO (1) RO121631B1 (pt)
WO (1) WO2001015699A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2230154T3 (es) * 1999-08-27 2005-05-01 Southern Research Institute Composiciones inyectables de buprenorfina y su utilizacion para reduccion del consumo de heroina y alcohol.
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
WO2003007782A2 (en) * 2001-06-29 2003-01-30 Medgraft Microtech, Inc. Biodegradable injectable implants and related methods of manufacture and use
EP1418862A4 (en) * 2001-06-29 2010-06-09 Leon J Lewandowski INDIVIDUALIZED SEARCH THERAPY
US20030130297A1 (en) 2001-07-06 2003-07-10 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
EP1404332A1 (en) * 2001-07-06 2004-04-07 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone related applications
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
EP1509182A4 (en) 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc IMPLANTABLE POLYMERS DEVICE FOR THE DELAYED RELEASE OF BUPRENORPHINE
US7041320B1 (en) * 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
WO2004078178A1 (en) * 2003-03-03 2004-09-16 Markus Heilig Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use
CN1777426A (zh) 2003-03-31 2006-05-24 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US7919499B2 (en) 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
FR2869801B1 (fr) * 2004-05-05 2008-09-12 Ethypharm Sa Procede de preparation de compositions a liberation prolongee et utilisation de ces compositions pour le traitement des affections chroniques du systeme nerveux central (snc)
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
DK1789076T3 (en) 2004-08-04 2016-04-11 Clinuvel Pharmaceuticals Ltd METHODS for inducing melanogenesis in a subject
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
WO2008106571A2 (en) * 2007-02-28 2008-09-04 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
ES2572157T3 (es) 2007-09-03 2016-05-30 Nanotherapeutics Inc Composiciones en forma de partículas para la administración de fármacos poco solubles
JP5502751B2 (ja) * 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
PL2326313T3 (pl) 2008-09-24 2015-08-31 Evonik Roehm Gmbh Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu
CA2738078C (en) * 2008-09-24 2015-12-29 Evonik Roehm Gmbh Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
CN104984343B (zh) * 2008-09-24 2019-04-02 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
US20100268191A1 (en) * 2009-04-21 2010-10-21 Medtronic Vascular, Inc. Drug Delivery Catheter using Frangible Microcapsules and Delivery Method
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US9566241B2 (en) 2012-02-21 2017-02-14 Auburn University Buprenorphine nanoparticle composition and methods thereof
WO2013156850A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN102836131A (zh) * 2012-09-28 2012-12-26 山东大学 丁丙诺啡皮下注射用缓释微球制剂及其制备方法
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
JP6135292B2 (ja) * 2013-05-10 2017-05-31 ニプロ株式会社 マイクロカプセル製剤の製造方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
WO2017147285A1 (en) 2016-02-23 2017-08-31 Biodelivery Sciences International, Inc. Sustained release buprenorphine microspheres (srbm) and methods of use thereof
CN109789137B (zh) 2016-09-13 2023-01-13 昱展新药生技股份有限公司 丁丙诺啡缓释制剂
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN114401746A (zh) * 2019-08-12 2022-04-26 耶路撒冷希伯来大学伊森姆研究发展有限公司 包括鸦片拮抗剂组合的药学组合物及复合材料及其使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US5143661A (en) * 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
FR2618674B1 (fr) 1987-07-30 1990-06-15 Ire Celltarg Sa Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
AU5741590A (en) 1989-05-04 1990-11-29 Southern Research Institute Improved encapsulation process and products therefrom
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5716631A (en) 1995-09-29 1998-02-10 Rdn Therapeutics Inc. Long acting narcotic analgesics and antagonists
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
ES2230154T3 (es) * 1999-08-27 2005-05-01 Southern Research Institute Composiciones inyectables de buprenorfina y su utilizacion para reduccion del consumo de heroina y alcohol.

Also Published As

Publication number Publication date
DE60015370T2 (de) 2006-03-09
CA2382577C (en) 2008-01-22
HUP0203613A3 (en) 2005-01-28
AU765496B2 (en) 2003-09-18
US20030152638A1 (en) 2003-08-14
CY1106043T1 (el) 2011-04-06
RO121631B1 (ro) 2008-01-30
ES2230154T3 (es) 2005-05-01
DE60015370D1 (de) 2004-12-02
AU7075100A (en) 2001-03-26
HUP0203613A2 (hu) 2003-02-28
KR20020053057A (ko) 2002-07-04
PL198334B1 (pl) 2008-06-30
JP2003508439A (ja) 2003-03-04
NZ517997A (en) 2002-11-26
CZ2002728A3 (cs) 2002-08-14
HK1046858A1 (en) 2003-01-30
EP1212061B1 (en) 2004-10-27
IL148343A0 (en) 2002-09-12
CN1248689C (zh) 2006-04-05
EA009080B1 (ru) 2007-10-26
EP1212061A1 (en) 2002-06-12
US6495155B1 (en) 2002-12-17
EA200200295A1 (ru) 2002-08-29
MXPA02002105A (es) 2003-12-11
NO20063239L (no) 2002-04-03
HK1046858B (zh) 2005-03-24
NO322650B1 (no) 2006-11-13
CN1382051A (zh) 2002-11-27
AU765496C (en) 2005-08-25
KR100730440B1 (ko) 2007-06-19
US7473431B2 (en) 2009-01-06
JP4913298B2 (ja) 2012-04-11
CN1788721A (zh) 2006-06-21
NO20020924D0 (no) 2002-02-26
PL354977A1 (en) 2004-03-22
CN100387228C (zh) 2008-05-14
WO2001015699A1 (en) 2001-03-08
NO20020924L (no) 2002-04-03
CA2382577A1 (en) 2001-03-08
ATE280579T1 (de) 2004-11-15
PT1212061E (pt) 2005-01-31
IL148343A (en) 2008-03-20

Similar Documents

Publication Publication Date Title
BR0013650A (pt) Composições injetáveis de micropartìculas de buprenorfina e seu uso
BR0009639A (pt) Composições de microesferas de naltrexona injetável e seu uso na redução do consumo de heroìna e álcool
US6525062B2 (en) Method of treating pain using nalbuphine and opioid antagonists
Carroll et al. Pharmacological properties of JDTic: a novel κ-opioid receptor antagonist
BRPI0511224A (pt) método para preparar uma composição contendo antagonistas de opióides, produto contendo antagonistas de opióides, composição contendo antagonistas de opióides, formulação de dosagem injetável, kit, método para prevenir ou tratar um efeito colateral associado com um opióide num paciente, e para tratar ou impedir dor num paciente
BR0109150A (pt) Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente
JP2003514013A (ja) 医薬組成物
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
MXPA03007885A (es) Norbuprenorfina n-but-3-enilo y metodos de uso.
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
JP2000513704A (ja) 麻薬禁断症候群に対する抗ミネラロコルチコイド化合物の新規な用途
Kamerling et al. Narcotic analgesics, their detection and pain measurement in the horse: a review
De Vry et al. Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine
EA200100871A1 (ru) Кристаллическая форма эплеренона, обладающая повышенной скоростью растворения
JP2004529959A (ja) 鎮痛剤組成物と手法
Divin et al. Comparison of the opioid receptor antagonist properties of naltrexone and 6β-naltrexol in morphine-naïve and morphine-dependent mice
BRPI0413607A (pt) composição farmacêutica para a prevenção e tratamento do vìcio em mamìferos
BRPI0413608A (pt) composição farmacêutica compreendendo um ligante alfa2delta e um antagonista de receptor opióide para a prevenção e tratamento de dependência quìmica em um mamìfero
AU9266698A (en) Acidic addition salts of morphine alkaloids and the application thereof
EP1555023A3 (en) Injectable buprenorphine microparticle compositions and their use
David et al. Antagonism of bremazocine‐induced urination as a test for kappa‐opioid receptor antagonists within the phenylpiperidine series
Kamei et al. Antinociceptive effect of lipopolysaccharide from Pantoea agglomerans on streptozotocin-induced diabetic mice
Funada et al. A new opioid analgesic KT90: Analgesia and dependence liability
CN117915916A (zh) 低剂量纳曲醇和其用途
Jacobson Biological evaluation of compounds for their physical dependence potential and abuse Liability. XIV. Animal Testing Committee of the Committee on Problems of Drug Dependence (1990)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BROOKWOOD PHARMACEUTICALS, INC. (US)

Free format text: TRANSFERIDO DE: SOUTHERN RESEARCH INSTITUTE

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.